The delay in tumor growth on treatment with anti-LAG-3 mAbs alone was not significant, whereas a statistical difference was observed between anti-PD-1–treated and IC mAb–treated mice (Fig. 6; P = 0.0201). Here, PDCD1 is linked to neoplasm.